CAR-T cell therapy for hematological malignancies: History, status and promise
For many years, the methods of cancer treatment are usually surgery, chemotherapy and radiation therapy. Although these methods help to improve the condition, most tumors still have a poor prognosis. In recent years, immunotherapy has great potential in tumor treatment. Chimeric antigen receptor T-c...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-11-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844023089843 |
| _version_ | 1827615974878085120 |
|---|---|
| author | Chao Wang Jianpeng Wang Shusheng Che Hai Zhao |
| author_facet | Chao Wang Jianpeng Wang Shusheng Che Hai Zhao |
| author_sort | Chao Wang |
| collection | DOAJ |
| description | For many years, the methods of cancer treatment are usually surgery, chemotherapy and radiation therapy. Although these methods help to improve the condition, most tumors still have a poor prognosis. In recent years, immunotherapy has great potential in tumor treatment. Chimeric antigen receptor T-cell immunotherapy (CAR-T) uses the patient's own T cells to express chimeric antigen receptors. Chimeric antigen receptor (CAR) recognizes tumor-associated antigens and kills tumor cells. CAR-T has achieved good results in the treatment of hematological tumors. In 2017, the FDA approved the first CAR-T for the treatment of B-cell acute lymphoblastic leukemia (ALL). In October of the same year, the FDA approved CAR-T to treat B-cell lymphoma. In order to improve and enhance the therapeutic effect, CAR-T has become a research focus in recent years. The structure of CAR, the targets of CAR-T treatment, adverse reactions and improvement measures during the treatment process are summarized. This review is an attempt to highlight recent and possibly forgotten findings of advances in chimeric antigen receptor T cell for treatment of hematological tumors. |
| first_indexed | 2024-03-09T09:18:15Z |
| format | Article |
| id | doaj.art-e17106b889a94d59b9d68977803b88ad |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-03-09T09:18:15Z |
| publishDate | 2023-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-e17106b889a94d59b9d68977803b88ad2023-12-02T07:04:12ZengElsevierHeliyon2405-84402023-11-01911e21776CAR-T cell therapy for hematological malignancies: History, status and promiseChao Wang0Jianpeng Wang1Shusheng Che2Hai Zhao3Department of Neurosurgery, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, Shandong, 266005, ChinaDepartment of Neurosurgery, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, Shandong, 266005, ChinaDepartment of Neurosurgery, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, Shandong, 266005, ChinaCorresponding author.; Department of Neurosurgery, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, Shandong, 266005, ChinaFor many years, the methods of cancer treatment are usually surgery, chemotherapy and radiation therapy. Although these methods help to improve the condition, most tumors still have a poor prognosis. In recent years, immunotherapy has great potential in tumor treatment. Chimeric antigen receptor T-cell immunotherapy (CAR-T) uses the patient's own T cells to express chimeric antigen receptors. Chimeric antigen receptor (CAR) recognizes tumor-associated antigens and kills tumor cells. CAR-T has achieved good results in the treatment of hematological tumors. In 2017, the FDA approved the first CAR-T for the treatment of B-cell acute lymphoblastic leukemia (ALL). In October of the same year, the FDA approved CAR-T to treat B-cell lymphoma. In order to improve and enhance the therapeutic effect, CAR-T has become a research focus in recent years. The structure of CAR, the targets of CAR-T treatment, adverse reactions and improvement measures during the treatment process are summarized. This review is an attempt to highlight recent and possibly forgotten findings of advances in chimeric antigen receptor T cell for treatment of hematological tumors.http://www.sciencedirect.com/science/article/pii/S2405844023089843Chimeric antigen receptorT cell immunotherapyHematological malignanciesTarget therapy |
| spellingShingle | Chao Wang Jianpeng Wang Shusheng Che Hai Zhao CAR-T cell therapy for hematological malignancies: History, status and promise Heliyon Chimeric antigen receptor T cell immunotherapy Hematological malignancies Target therapy |
| title | CAR-T cell therapy for hematological malignancies: History, status and promise |
| title_full | CAR-T cell therapy for hematological malignancies: History, status and promise |
| title_fullStr | CAR-T cell therapy for hematological malignancies: History, status and promise |
| title_full_unstemmed | CAR-T cell therapy for hematological malignancies: History, status and promise |
| title_short | CAR-T cell therapy for hematological malignancies: History, status and promise |
| title_sort | car t cell therapy for hematological malignancies history status and promise |
| topic | Chimeric antigen receptor T cell immunotherapy Hematological malignancies Target therapy |
| url | http://www.sciencedirect.com/science/article/pii/S2405844023089843 |
| work_keys_str_mv | AT chaowang cartcelltherapyforhematologicalmalignancieshistorystatusandpromise AT jianpengwang cartcelltherapyforhematologicalmalignancieshistorystatusandpromise AT shushengche cartcelltherapyforhematologicalmalignancieshistorystatusandpromise AT haizhao cartcelltherapyforhematologicalmalignancieshistorystatusandpromise |